Lung Transplant Rejection Pipeline Review H1 2018 - Reviews Key Companies Involved in Therapeutics and Enlists All Their Major & Minor Projects - ResearchAndMarkets.com

DUBLIN--()--The "Lung Transplant Rejection - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

The pipeline guide provides a snapshot of the global therapeutic landscape of Lung Transplant Rejection (Immunology).

The pipeline guide reviews pipeline therapeutics for Lung Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Lung Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Lung Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Lung Transplant Rejection (Immunology).

Companies Mentioned

  • Astellas Pharma Inc
  • Kamada Ltd
  • MimeTech Srl
  • Novartis AG
  • Quark Pharmaceuticals Inc
  • TxCell SA

Key Topics Covered

  1. Introduction
  2. Report Coverage
  3. Lung Transplant Rejection - Overview
  4. Lung Transplant Rejection - Therapeutics Development
  5. Pipeline Overview
  6. Pipeline by Companies
  7. Products under Development by Companies
  8. Lung Transplant Rejection - Therapeutics Assessment
  9. Assessment by Target
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. Lung Transplant Rejection - Companies Involved in Therapeutics Development
  14. Astellas Pharma Inc
  15. Kamada Ltd
  16. MimeTech Srl
  17. Novartis AG
  18. Quark Pharmaceuticals Inc
  19. TxCell SA
  20. Lung Transplant Rejection - Drug Profiles
  21. alpha-1 proteinase inhibitor (human) - Drug Profile
  22. Product Description
  23. Mechanism Of Action
  24. R&D Progress
  25. BC-1261 - Drug Profile
  26. Product Description
  27. Mechanism Of Action
  28. R&D Progress
  29. FX-06 - Drug Profile
  30. Product Description
  31. Mechanism Of Action
  32. R&D Progress
  33. MT-8 - Drug Profile
  34. Product Description
  35. Mechanism Of Action
  36. R&D Progress
  37. QPI-1024 - Drug Profile
  38. Product Description
  39. Mechanism Of Action
  40. R&D Progress
  41. QPLI-1 - Drug Profile
  42. Product Description
  43. Mechanism Of Action
  44. R&D Progress
  45. R-554 - Drug Profile
  46. Product Description
  47. Mechanism Of Action
  48. R&D Progress
  49. R-801 - Drug Profile
  50. Product Description
  51. Mechanism Of Action
  52. R&D Progress
  53. tacrolimus - Drug Profile
  54. Product Description
  55. Mechanism Of Action
  56. R&D Progress
  57. tiprelestat - Drug Profile
  58. Product Description
  59. Mechanism Of Action
  60. R&D Progress
  61. TX-200 - Drug Profile
  62. Product Description
  63. Mechanism Of Action
  64. R&D Progress
  65. Zortress - Drug Profile
  66. Product Description
  67. Mechanism Of Action
  68. R&D Progress
  69. Lung Transplant Rejection - Dormant Projects
  70. Lung Transplant Rejection - Product Development Milestones
  71. Featured News & Press Releases

For more information about this report visit https://www.researchandmarkets.com/research/65cx2m/lung_transplant?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immunosuppressive Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immunosuppressive Drugs